To characterize the genomic alterations and investigate the functional consequences of these alterations in isolated tumor cells from MF and CD30+ LPD.
ID
Source
Brief title
Condition
- Lymphomas non-Hodgkin's T-cell
- Lymphomas non-Hodgkin's T-cell
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The main study parameters are the prevalence of 1. genetic alterations
(mutations, copy number alterations, translocations and DNA methylation) and
2.short term cultures as well as mouse models will be used to evaluate
cytotoxic effect of selected drugs, including (but not limited to) anti CD30
antibodies, and inhibitors of JAK/STAT signalling.
Secondary outcome
Development of CTCL cell lines.
Background summary
Cutaneous T-cell lymphoma (CTCL) are a rare and heterogeneous group of
lymphomas that originate in the skin. Around 50% of CTCL are patients with
mycosis fungoides (MF) which is the most common type of cutaneous lymphoma.
Sezary syndrome (SS) is a rare type of CTCL in which tumor cells are found in
skin, lymph nodes and blood. Patients with SS present with a pruritic
erythrodermia, lymphadenopathy and have a poor prognosis. The second most
common type of CTCL is the spectrum of CD30+ lymphoproliferative diseases (LPD)
that includes on the one end cases of CD30+ primary cutaneous anaplastic large
cell lymphoma (pcALCL) and on the other end lymphomatoid papulosis (LyP) as
well as intermediate cases. At present CTCL are incurable with the exception of
allogenic stem cell transplantation which has considerable treatment related
morbidity and mortality. Insight in the dominant oncogenetic pathways driving
CTCL is still limited and further insight in the molecular alterations
underlying the development and progression MF, SS and CD30+ LPD might provide
new therapeutic targets that are urgently needed in particular in patients with
advanced disease.
Study objective
To characterize the genomic alterations and investigate the functional
consequences of these alterations in isolated tumor cells from MF and CD30+
LPD.
Study design
Prospective, observational study
Study burden and risks
Two four mm skin biopsies will be obtained from lesional skin at a routine
visits to the clinic. There are no high risks to be expected with this
approach. There is only a (very low) risk (<5%) of a wound infection after
biopsy.
Albinusdreef 2
Leiden 1333 ZA
NL
Albinusdreef 2
Leiden 1333 ZA
NL
Listed location countries
Age
Inclusion criteria
Age between 18-90 years
Established diagnosis of MF, SS, LyP, or pc ALCL
Skin lesions
Not receiving therapy
Exclusion criteria
Ongoing infection
Patients younger than 18 years of age
Design
Recruitment
metc-ldd@lumc.nl
metc-ldd@lumc.nl
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL84066.058.23 |